Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
about
Profiling of substrate specificity of SARS-CoV 3CLSynthesis of bioactive natural products as protein inhibitors.Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.A practical total synthesis of the microbial alkaline proteinase inhibitor (MAPI).
P2860
Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@ast
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@en
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@nl
type
label
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@ast
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@en
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@nl
prefLabel
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@ast
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@en
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@nl
P2093
P1476
Evaluation of peptide-aldehyde ...... proteolysis-resistant mutant.
@en
P2093
Ayumi Makino
Hiroyuki Konno
Hiroyuki Saito
Kazuto Nosaka
Kenichi Akaji
Mari Onozuka
P304
P356
10.1016/J.BMC.2008.09.057
P407
P577
2008-09-26T00:00:00Z